Akèy › Kansè trakt bilè
Etid klinik pou Kansè trakt bilè ap rekrite nan Etazini
40 etid pou Kansè trakt bilè ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX18 etid
- Los Angeles, CA11 etid
- Boston, MA11 etid
- New York City, NY10 etid
- Nashville, TN9 etid
- San Antonio, TX8 etid
- Baltimore, MD8 etid
- Washington, DC7 etid
- Arlington, VA7 etid
- Pittsburgh, PA7 etid
- Baldwin Park, CA6 etid
- Cleveland, OH6 etid
- Dallas, TX6 etid
- Columbus, OH6 etid
- Madison, WI6 etid
- Philadelphia, PA6 etid
- Detroit, MI5 etid
- Louisville, KY5 etid
- Tampa, FL5 etid
- Miami, FL5 etid
- Orange, CA4 etid
- Seattle, WA4 etid
- Aurora, CO4 etid
- Queens, NY4 etid
- Orlando, FL4 etid
- Buffalo, NY3 etid
- Edison, NJ3 etid
- Santa Monica, CA3 etid
- Salt Lake City, UT3 etid
- St. Louis, MO3 etid
- San Diego, CA3 etid
- Grand Rapids, MI3 etid
- Chicago, IL3 etid
- Tucson, AZ3 etid
- Providence, RI3 etid
- Denver, CO3 etid
- Portland, OR3 etid
- Birmingham, AL3 etid
Pa eta
- Alabama3 etid
- Arizona4 etid
- Colorado7 etid
- Connecticut3 etid
- Distrik Columbia4 etid
- Florid14 etid
- Georgia4 etid
- Illinois5 etid
- Kalifòni20 etid
- Kentucky6 etid
- Maryland11 etid
- Massachusetts11 etid
- Michigan9 etid
- Minnesota5 etid
- Missouri4 etid
- New Jersey5 etid
- New York15 etid
- Ohio10 etid
- Oregon3 etid
- Pennsylvania10 etid
- Rhode Island3 etid
- Tennessee10 etid
- Texas23 etid
- Utah4 etid
- Virginia9 etid
- Washington5 etid
- Wisconsin6 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Ap rekriteEtid obsèvasyon
Laj 2 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT01950572A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06760819AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06219941A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07265674Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05482893A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07221253A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06428409Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT05523947Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Ap rekriteFaz 2
Laj 18 a 130 · Tout sèks · Mizajou Sep 23, 2026 · NCT05489211Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Ap rekriteFaz 2
Laj 19 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07146646Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06282575SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT07812805Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06548412AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Sep 4, 2026 · NCT07038343Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06084481Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 99 · Tout sèks · Mizajou Aug 24, 2026 · NCT05517811A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Aug 19, 2026 · NCT06467357A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06330064D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT06622057A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
Laj 8 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT05503797Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT06101277A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT07458347Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.